BioLife Solutions
BLFS
16 hedge funds and large institutions have $653K invested in BioLife Solutions in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
23% more funds holding
Funds holding: 13 → 16 (+3)
11% less capital invested
Capital invested by funds: $736K → $653K (-$83K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$18.9K |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$18.4K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.23K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.91K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$567 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$8.43K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$35 |
| 3 |
Morgan Stanley
New York
|
-$6 |
BLFS Hedge Fund Activity: Q1 2016 in Review
16 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in BioLife Solutions (BLFS) for Q1 2016, worth a combined $653K — down 11% from $736K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BLFS positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $18.9K. The largest seller was UBS Group, cutting an estimated $8.43K.
- 16 institutional investors held BioLife Solutions (BLFS) as of Q1 2016, up from 13 in Q4 2015.
- Funds reported $653K of BioLife Solutions stock for Q1 2016, down 11% quarter-over-quarter.
- 4 funds opened new BioLife Solutions positions in Q1 2016 and 1 closed out, a net change of +3 holders.
- The largest BioLife Solutions buyer in Q1 2016 was Citadel Advisors, an estimated $18.9K added.
- The largest BioLife Solutions seller in Q1 2016 was UBS Group, an estimated $8.43K sold.
Based on aggregated 13F filings for Q1 2016.